Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash from Financing Activities data on file, last reported at $2.7 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $2.7 million, up 476.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (up 49.76% YoY), and the FY2025 annual result was $4.8 million, down 71.17% from the prior year.
• Cash from Financing Activities slipped to $2.7 million in Q1 2026 per CRBU's latest filing, from $4.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $135.1 million in Q3 2023 and troughed at -$43000.0 in Q4 2023.
• A 5-year average of $10.6 million and a median of $654000.0 in 2022 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 20561.77% in 2023 and fell as far as 133.86% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $127000.0 in 2022, then plunged by 133.86% to -$43000.0 in 2023, then surged by 9083.72% to $3.9 million in 2024, then gained by 5.36% to $4.1 million in 2025, then plunged by 33.76% to $2.7 million in 2026.
• Business Quant data shows CRBU's Cash from Financing Activities at $2.7 million in Q1 2026, $4.1 million in Q4 2025, and $277000.0 in Q3 2025.